In 2022, the A-share market continued to fluctuate. In this context, in order to demonstrate the company’s confidence in its products, many fund managers have successively purchased their own fund products. In 2022, there were 22 companies that had or planned to carry out fund self purchase. As of January 26, the total self purchase amount reached 460 million yuan.
On January 26, Ge Lan, the fund manager of China Europe Fund and the “goddess of medicine”, bought his own fund, which became the screen news in the industry on that day. China Europe Fund announced that the company will purchase 50 million yuan from China Europe medical health and China Europe medical innovation funds; Fund manager Glenn will also purchase 2 million yuan from the above two funds.
China Securities Journal reporter noted that recently, a number of fund companies have also come up with “real gold and silver” to buy their own funds.
Gran’s “real gold and silver” shot
As the top fund manager in the pharmaceutical industry, Glenn of China Europe Fund has been at the forefront of the storm. In the fund’s 2021 fourth quarter report just disclosed, Glenn has ranked among the 100 billion fund managers.
With the continuous adjustment of the market, the reporter of China Securities Journal noted that China Europe Fund and Glenn are ready to sell. On January 26, China Europe Fund announced that the company would purchase a total of 50 million yuan of China Europe medical health hybrid and China Europe medical innovation shares with its own funds within 30 trading days from the date of the announcement, and hold them for more than three years. At the same time, fund manager Glenn will also purchase a total of 2 million yuan of China EU medical and health hybrid and China EU medical innovation stocks with his own funds within 30 trading days from the date of announcement, and hold them for more than three years.
As industry theme funds, China Europe medical and health fund and China Europe medical innovation fund mainly focus on investment in the medical sector. After the rapid rise in the past two years and the repeated disturbance of covid-19 epidemic, the medical sector fluctuates greatly as a whole. With the rapid adjustment in recent quarters, the long-term investment cost performance of individual stocks in the high-quality medical industry has further improved. Looking forward to 2022, the fund manager Ge Lan and the China Europe Fund research team believe that the basis for the long-term growth of the pharmaceutical and biological industry has not changed, and the policy orientation is generally positive and stable. In the overall transformation period of the industry and the post epidemic era, enterprises pay more attention to cultivating internal skills, and the upstream and downstream of the industrial chain are more perfect. Therefore, they are optimistic about the long-term investment opportunities of the industry.
the self purchase of the industry exceeds 400 million yuan
On January 26, Hua’an Fund announced that from January 26 to February 25, it used its inherent funds to purchase the partial share public offering fund of the company, with a total contribution of no less than 50 million yuan. Hua’an fund also said that the follow-up company will continue to apply for its partial share public offering fund.
With the continuous fluctuation of the market, the self purchase behavior of fund companies is becoming more and more frequent. On January 25, Bodao Fund announced that on January 24, the company invested 10 million yuan of its own funds to purchase some of its funds, including 3 million yuan of Bodao Jiafeng mixed class A shares, 3 million yuan of Bodao growth Zhihang shares, 2 million yuan of Bodao consumption Zhihang shares and 2 million yuan of Bodao Shengyan mixed class A shares. For the South MSCI China A50 interconnection ETF Feeder Fund announced on January 11, the South Fund Company subscribed 200 million yuan with its own funds, which can be called a strong self purchase since 2022.
According to the data, since January, a total of 22 public offerings, including South Fund, Xingzheng Global Fund, e fund, Harvest Fund and Wells Fargo fund, have announced self purchase of their fund products. As of January 26, the cumulative net purchase amount was 460 million yuan.
A person from a fund company said frankly that on the one hand, self purchase is a period when the market fluctuates violently and the market sentiment is relatively pessimistic. The fund company makes self purchase to convey a kind of confidence to investors; On the other hand, self purchase is sometimes a reflection of the fund company’s adjustment of its own funds. Benefiting from the rapid development of the fund industry in the past two years, some fund companies have more capital surplus, and the company itself also has the demand for wealth management.
Although self purchase has a certain role in boosting confidence, it does not mean that self purchased funds will be able to make money. Fund self purchase is only a market phenomenon. The reasons and starting points of self purchase are different. Ordinary investors still need to be rational in the face of this situation.
